PARIS, Nov 26, 2024 (BSS/AFP) - The number of new HIV infections and deaths
has fallen across the world, marking significant progress in the fight
against the disease.

But HIV is far from being stamped out, health experts warn ahead of World
AIDS Day on Sunday.

- Uneven progress -

During the 2010s, the number of HIV infections across the world declined by a
fifth, according to a major study published in The Lancet HIV journal on
Tuesday.

Deaths related to HIV, which are generally caused by other diseases during
the late stages of AIDS, fell by about 40 percent to below a million a year,
the study said.

The decline was mainly driven by improving rates in sub-Saharan Africa, which
is by far the hardest-hit region in the global epidemic.

However infections did not go down everywhere. Other regions, such as Eastern
Europe and the Middle East, saw HIV numbers increase.

And the world remains far from the United Nations target of virtually
eradicating AIDS-related deaths by 2030, the researchers said.

"The world has made remarkable global progress to significantly reduce the
number of new HIV infections," said lead study author Hmwe Kyu of the US-
based Institute For Health Metrics and Evaluation.

"More than a million people acquire a new HIV infection each year and, of the
40 million people living with HIV, a quarter are not receiving treatment,"
she said in a statement.

- Effective tools -

Preventative treatments called Pre-Exposure Prophylaxis (PrEP) have proven to
be a powerful tool in the fight against HIV.

These daily pills reduce the risk of getting HIV from sex by around 99
percent.

They have helped drive down HIV rates in many countries. In some, such as
France, health authorities are urging PrEP to be made more available to more
people, rather than just men who have sex with men.

"It is something that can be used by anyone who needs it at some point in
their sexual life," French infectious disease specialist Pierre Delobel told
a press conference.

For people who have been infected with HIV, antiretroviral therapy can reduce
the amount of the virus in their blood to undetectable levels.

An undetectable viral load means that there is less than a one percent chance
that breastfeeding mothers pass HIV onto their babies, according to the US
Centers for Disease Control and Prevention.

- New drug raises hopes -

These tools have worked well in wealthier countries but the high costs have
meant that poorer countries -- such as in Africa -- have often been left
behind.

There are fears that this history could repeat for a new drug that has been
hailed as a potential game-changer in the battle against HIV.

Early trials have found that the antiretroviral treatment lenacapavir is 100
percent effective in preventing HIV infection. And it only needs to be
injected twice a year, making the drug far easier to administer than current
regimens requiring daily pills.

US pharmaceutical giant Gilead has been charging around $40,000 per person
per a year for the treatment in several countries.

But researchers have estimated the drug could be made for as little as $40,
calling on Gilead to allow for cheaper access in hard-hit nations.

Last month, Gilead announced it had signed licensing deals with six generic
drugmakers to produce and sell lenacapavir in lower-income countries.

While experts largely welcomed the move, some noted that millions of people
with HIV live in countries not included in the deal.

The twice-yearly injection is also hoped to help get around another problem
for administering HIV drugs -- the stigma that comes along with having the
disease.

- What about a vaccine? -

Despite decades of effort, a vaccine for HIV remains elusive.

But the lenacapavir shot is "like having a vaccine basically", Andrew Hill, a
researcher at the UK's Liverpool University, told AFP earlier this year.

A handful of patients have also been effectively cured of HIV.

But these cures happen only after a patient endures a brutal stem cell
transplant for their leukaemia, so is not an option for almost all people
living with HIV.